Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major

Roswitha Lüftinger, Natalia Zubarovskaya, Jacques‐Emmanuel Galimard, Annamária Cseh, Elisabeth Salzer, Franco Locatelli, Mattia Algeri, Akif Yeşilipek, Josu de la Fuente, Antonella Isgrò, Amal Al-Seraihy, Emanuele Angelucci, Frans J. Smiers, Giorgia La La Nasa, Marco Zecca, Tunç Fışgın, Emel Ünal, Katharina Kleinschmidt, Christina Peters, Arjan C. Lankester, Selim Corbacioglu, on behalf of the EBMT Pediatric Diseases, Inborn Errors Working Parties